Pradaxa User's Labeling Claims Preempted, Calif. Judge Rules

Law360 (November 8, 2019, 11:18 PM EST) -- A California state judge on Friday handed Boehringer Ingelheim Pharmaceuticals a big win in consolidated litigation over its blood thinner Pradaxa, finding that federal law preempts a woman's claims that the pharmaceutical company should've more adequately warned doctors of the drug's internal bleeding risks.

The decision echoes a September ruling by a Connecticut state judge overseeing consolidated litigation in that state over similar claims against Boehringer Ingelheim. In that case, Connecticut Superior Court Judge Carl Schuman upheld a jury's finding that Pradaxa caused a man's internal bleeding, but he also ruled that federal labeling law preempted a separate allegation the company...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS